Susceptible loci associated with autoimmune disease as potential biomarkers for checkpoint inhibitor-induced immune-related adverse events
Open accessThe DOI matches its Crossref record; 212 of the 213 references it cites were found in a registry or an index.
Abstract
Unprecedented successes regarding cancer immunotherapy have been achieved, in which therapeutic agents are used to target immune cells rather than cancer cells. The most effective immunotherapy to date is the group of immune checkpoint inhibitors (CPI), targeting, for example, cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) or programmed cell death protein (PD-1). TThe combination of these therapies (anti-PD-1 with anti-CTLA-4) induces high response rates, and seem to be increased further when applied in early-stage disease. However, combined CTLA-4 plus PD-1 blockade causes frequent high-grade immune-related adverse events (irAE). To date, research on biological mechanism of irAEs is scarce and no widely accepted biomarkers predicting onset of severe irAEs have been identified. The similarity of irAEs to autoimmune disorders fuels the hypothesis that irAEs may be linked to susceptible genetic loci related to various autoimmune diseases. In this review, we extensively searched for susceptible loci associated with various autoimmune diseases, and pooled them in groups most likely to be associated with CPI-induced irAEs. These sets could be used in future research on predicting irAEs and guide physicians in a more refined and personal manner.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“While genetic determinants for autoimmune disease are numerous (Hoefsmit et al., 2019), genetic pre-disposition to irAEs is less well-defined.”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Hoefsmit et al., 2019
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157 · cited 2×
“Severe adverse events (AE) from CPI are observed in about 15% of patients treated with anti-PD-1/PD-L1, 20%–30% with ipilimumab and in up to 60% in ipilimumab/nivolumab combination therapy in late-stage disease.(4) 11–17 These AEs, called immune-related (ir)AEs or AEs of special interest, closely resemble autoimmune d…”
BackgroundHerbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C. D., Ahn, M.-J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01281-7 · Cited by 6,449
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1510665 · Cited by 5,807
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519
A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease
Ogura, Y., Bonen, D. K., Inohara, N., Nicolae, D. L., Chen, F. F., Ramos, R., Britton, H., Moran, T., Karaliuskas, R., Duerr, R. H., et al. (2001) · Nature · doi:10.1038/35079114 · Cited by 5,030
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
Postow, M. A., Sidlow, R., & Hellmann, M. D. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1703481 · Cited by 4,849
Complement factor H polymorphism in age-related macular degeneration
Klein, R. J., Zeiss, C., Chew, E. Y., Tsai, J.-Y., Sackler, R. S., Haynes, C., Henning, A. K., SanGiovanni, J. P., Mane, S. M., Mayne, S. T., et al. (2005) · Science · doi:10.1126/science.1109557 · Cited by 4,492
Nivolumab plus Ipilimumab in Advanced Melanoma
Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
Ansell, S. M., Lesokhin, A. M., Borrello, I., Halwani, A., Scott, E. C., Gutierrez, M., Schuster, S. J., Millenson, M. M., Cattry, D., Freeman, G. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411087 · Cited by 3,560
Weber, J. S., D'Angelo, S. P., Minor, D., Hodi, F. S., Gutzmer, R., Neyns, B., Hoeller, C., Khushalani, N. I., Miller, W. H., Lao, C. D., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70076-8 · Cited by 2,676
Wang, D. Y., Salem, J.-E., Cohen, J. V., Chandra, S., Menzer, C., Ye, F., Zhao, S., Das, S., Beckermann, K. E., Ha, L., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.3923 · Cited by 2,674
Genetics and pathogenesis of inflammatory bowel disease
Khor, B., Gardet, A., & Xavier, R. J. (2011) · Nature · doi:10.1038/nature10209 · Cited by 2,614
Liu, J. Z., van Sommeren, S., Huang, H., Ng, S. C., Alberts, R., Takahashi, A., Ripke, S., Lee, J. C., Jostins, L., Shah, T., et al. (2015) · Nature Genetics · doi:10.1038/ng.3359 · Cited by 2,603
Haanen, J. B. A. G., Carbonnel, F., Robert, C., Kerr, K. M., Peters, S., Larkin, J., & Jordan, K. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx225 · Cited by 2,367 · cited 1×
“13 19–21 Severe irAEs can be managed with immune-modulatory medications, such as steroids, anti-tumour necrosis factor-alpha (TNF-α) antibody (eg, infliximab or inflectra), mycophenolate mofetil or calcineurin inhibitors like tacrolimus and cyclosporine.(22) While reversal in the majority of cases will be achieved, lo…”
BackgroundFulminant Myocarditis with Combination Immune Checkpoint Blockade
Johnson, D. B., Balko, J. M., Compton, M. L., Chalkias, S., Gorham, J., Xu, Y., Hicks, M., Puzanov, I., Alexander, M. R., Bloomer, T. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1609214 · Cited by 2,308
Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease
Ueda, H., Howson, J. M. M., Esposito, L., Heward, J., Snook, Chamberlain, G., Rainbow, D. B., Hunter, K. M. D., Smith, A. N., Di Genova, G., et al. (2003) · Nature · doi:10.1038/nature01621 · Cited by 2,175
Immune-related adverse events with immune checkpoint blockade: a comprehensive review
Michot, J. M., Bigenwald, C., Champiat, S., Collins, M., Carbonnel, F., Postel-Vinay, S., Berdelou, A., Varga, A., Bahleda, R., Hollebecque, A., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2015.11.016 · Cited by 2,127
Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation
Anderson, A. C., Joller, N., & Kuchroo, V. K. (2016) · Immunity · doi:10.1016/j.immuni.2016.05.001 · Cited by 2,096
SLCO1B1 Variants and Statin-Induced Myopathy — A Genomewide Study
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801936 · Cited by 2,043
Begovich, A. B., Carlton, V. E. H., Honigberg, L. A., Schrodi, S. J., Chokkalingam, A. P., Alexander, H. C., Ardlie, K. G., Huang, Q., Smith, A. M., Spoerke, J. M., et al. (2004) · The American Journal of Human Genetics · doi:10.1086/422827 · Cited by 1,502
A functional variant of lymphoid tyrosine phosphatase is associated with type I diabetes
Bottini, N., Musumeci, L., Alonso, A., Rahmouni, S., Nika, K., Rostamkhani, M., MacMurray, J., Meloni, G. F., Lucarelli, P., Pellecchia, M., et al. (2004) · Nature Genetics · doi:10.1038/ng1323 · Cited by 1,424
Rizvi, N. A., Mazières, J., Planchard, D., Stinchcombe, T. E., Dy, G. K., Antonia, S. J., Horn, L., Lena, H., Minenza, E., Mennecier, B., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70054-9 · Cited by 1,415
Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab
Weber, J. S., Kähler, K. C., & Hauschild, A. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.41.6750 · Cited by 1,415 · cited 1×
“AEs can be found in any organ or tissue of the body, usually develop within the first 3 months of treatment with CPI (ranging from days after start-up to 1 year after cessation of therapy) and require prompt management.(18) The most prevalent irAEs are gastroin-”
BackgroundHLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol
Hung, S.-I., Chung, W.-H., Liou, L.-B., Chu, C.-C., Lin, M., Huang, H.-P., Lin, Y.-L., Lan, J.-L., Yang, L.-C., Hong, H.-S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409500102 · Cited by 1,284
Eggermont, A. M. M., Chiarion-Sileni, V., Grob, J.-J., Dummer, R., Wolchok, J. D., Schmidt, H., Hamid, O., Robert, C., Ascierto, P. A., Richards, J. M., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70122-1 · Cited by 1,262 · cited 1×
“athies and nephritis are less frequently reported.(12) 13 19–21 Severe irAEs can be managed with immune-modulatory medications, such as steroids, anti-tumour necrosis factor-alpha (TNF-α) antibody (eg, infliximab or inflectra), mycophenolate mofetil or calcineurin inhibitors like tacrolimus and cyclosporine.”
BackgroundGenome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci
BIRAC Consortium, Stahl, E. A., YEAR Consortium, Raychaudhuri, S., Remmers, E. F., Xie, G., Eyre, S., Thomson, B. P., Li, Y., Kurreeman, F. A. S., et al. (2010) · Nature Genetics · doi:10.1038/ng.582 · Cited by 1,253
Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma
Weber, J. S., Hodi, F. S., Wolchok, J. D., Topalian, S. L., Schadendorf, D., Larkin, J., Sznol, M., Long, G. V., Li, H., Waxman, I. M., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2015.66.1389 · Cited by 1,158
Barroso-Sousa, R., Barry, W. T., Garrido-Castro, A. C., Hodi, F. S., Min, L., Krop, I. E., & Tolaney, S. M. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2017.3064 · Cited by 1,115
Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity
Collaborative Association Study of Psoriasis (CASP), Tsoi, L. C., Genetic Analysis of Psoriasis Consortium, Psoriasis Association Genetics Extension, Wellcome Trust Case Control Consortium 2, Spain, S. L., Knight, J., Ellinghaus, E., Stuart, P. E., Capon, F., et al. (2012) · Nature Genetics · doi:10.1038/ng.2467 · Cited by 1,024
Bentham, J., Morris, D. L., Cunninghame Graham, D. S., Pinder, C. L., Tombleson, P., Behrens, T. W., Martín, J., Fairfax, B. P., Knight, J. C., Chen, L., et al. (2015) · Nature Genetics · doi:10.1038/ng.3434 · Cited by 1,020
A Mutation in the Surfactant Protein C Gene Associated with Familial Interstitial Lung Disease
Nogee, L. M., Dunbar, A. E., Wert, S. E., Askin, F., Hamvas, A., & Whitsett, J. A. (2001) · New England Journal of Medicine · doi:10.1056/nejm200102223440805 · Cited by 929
HLA-A*3101 and Carbamazepine-Induced Hypersensitivity Reactions in Europeans
McCormack, M., Alfirevic, A., Bourgeois, S., Farrell, J. J., Kasperavičiūtė, D., Carrington, M., Sills, G. J., Marson, T., Jia, X., de Bakker, P. I. W., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1013297 · Cited by 925
Coinhibitory Pathways in Immunotherapy for Cancer
Baumeister, S. H., Freeman, G. J., Dranoff, G., & Sharpe, A. H. (2016) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032414-112049 · Cited by 910
Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma
Blank, C. U., Rozeman, E. A., Fanchi, L. F., Sikorska, K., van de Wiel, B., Kvistborg, P., Krijgsman, O., van den Braber, M., Philips, D., Broeks, A., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0198-0 · Cited by 880
Self-citationManagement of toxicities of immune checkpoint inhibitors
Spain, L., Diem, S., & Larkin, J. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.02.001 · Cited by 854 · cited 1×
“While reversal in the majority of cases will be achieved, long-term hormonal substitution therapy for endocrine disorders occurs regularly.(15) As only a subset of patients treated with CPI develop severe AEs, it would be advantageous to upfront identify patients most likely to experience these toxicities.”
BackgroundGenome-wide association study in alopecia areata implicates both innate and adaptive immunity
Petukhova, L., Duvic, M., Hordinsky, M., Norris, D., Price, V., Shimomura, Y., Kim, H., Singh, P., Lee, A., Chen, W. V., et al. (2010) · Nature · doi:10.1038/nature09114 · Cited by 830
The Programmed Death-1 (PD-1) Pathway Regulates Autoimmune Diabetes in Nonobese Diabetic (NOD) Mice
Ansari, M. J. I., Salama, A. D., Chitnis, T., Smith, R. N., Yagita, H., Akiba, H., Yamazaki, T., Azuma, M., Iwai, H., Khoury, S. J., et al. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20022125 · Cited by 814
Gateva, V., Sandling, J. K., Hom, G., Taylor, K. E., Chung, S. A., Sun, X., Ortmann, W., Kosoy, R., Ferreira, R. C., Nordmark, G., et al. (2009) · Nature Genetics · doi:10.1038/ng.468 · Cited by 810
Genome-wide association study identifies multiple susceptibility loci for pulmonary fibrosis
Fingerlin, T. E., Murphy, E., Zhang, W., Peljto, A. L., Brown, K. K., Steele, M. P., Loyd, J. E., Cosgrove, G. P., Lynch, D., Groshong, S., et al. (2013) · Nature Genetics · doi:10.1038/ng.2609 · Cited by 809
Nistico, L. (1996) · Human Molecular Genetics · doi:10.1093/hmg/5.7.1075 · Cited by 809
New loci associated with kidney function and chronic kidney disease
Köttgen, A., Pattaro, C., Böger, C. A., Fuchsberger, C., Olden, M., Glazer, N. L., Parsa, A., Gao, X., Yang, Q., Smith, A. V., et al. (2010) · Nature Genetics · doi:10.1038/ng.568 · Cited by 804
Cleynen, I., Boucher, G., Jostins, L., Schumm, L. P., Zeissig, S., Ahmad, T., Andersen, V., Andrews, J. M., Annese, V., Brand, S., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00465-1 · Cited by 779
Blank, C. U., Haanen, J. B., Ribas, A., & Schumacher, T. N. (2016) · Science · doi:10.1126/science.aaf2834 · Cited by 748
Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions
Hung, S.-I., Chung, W.-H., Jee, S.-H., Chen, W.-C., Chang, Y.-T., Lee, W.-R., Hu, S.-L., Wu, M.-T., Chen, G.-S., Wong, T.-W., et al. (2006) · Pharmacogenetics and Genomics · doi:10.1097/01.fpc.0000199500.46842.4a · Cited by 680
Park, J.-H., Wacholder, S., Gail, M. H., Peters, U., Jacobs, K. B., Chanock, S. J., & Chatterjee, N. (2010) · Nature Genetics · doi:10.1038/ng.610 · Cited by 678
Genetic Association of the R620W Polymorphism of Protein Tyrosine Phosphatase PTPN22 with Human SLE
Kyogoku, C., Ortmann, W. A., Lee, A., Selby, S., Carlton, V. E. H., Chang, M., Ramos, P., Baechler, E. C., Batliwalla, F. M., Novitzke, J., et al. (2004) · The American Journal of Human Genetics · doi:10.1086/423790 · Cited by 672
Hua, C., Boussemart, L., Mateus, C., Routier, E., Boutros, C., Cazenave, H., Viollet, R., Thomas, M., Roy, S., Benannoune, N., et al. (2016) · JAMA Dermatology · doi:10.1001/jamadermatol.2015.2707 · Cited by 655
High-density genetic mapping identifies new susceptibility loci for rheumatoid arthritis
Syndicate, B. I. R. A. G. A. G. S., Eyre, S., Wellcome Trust Case Control Consortium, Bowes, J., Diogo, D., Lee, A., Barton, A., Martin, P., Zhernakova, A., Stahl, E., et al. (2012) · Nature Genetics · doi:10.1038/ng.2462 · Cited by 653
Multiple loci associated with indices of renal function and chronic kidney disease
Köttgen, A., Glazer, N. L., Dehghan, A., Hwang, S.-J., Katz, R., Li, M., Yang, Q., Gudnason, V., Launer, L. J., Harris, T. B., et al. (2009) · Nature Genetics · doi:10.1038/ng.377 · Cited by 647
Charmandari, E., Nicolaides, N. C., & Chrousos, G. P. (2014) · The Lancet · doi:10.1016/s0140-6736(13)61684-0 · Cited by 644
Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders
Johnson, D. B., Sullivan, R. J., Ott, P. A., Carlino, M. S., Khushalani, N. I., Ye, F., Guminski, A., Puzanov, I., Lawrence, D. P., Buchbinder, E. I., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2015.4368 · Cited by 642
Noth, I., Zhang, Y., Ma, S.-F., Flores, C., Barber, M., Huang, Y., Broderick, S. M., Wade, M. S., Hysi, P., Scuirba, J., et al. (2013) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(13)70045-6 · Cited by 614
Fine-mapping inflammatory bowel disease loci to single-variant resolution
International Inflammatory Bowel Disease Genetics Consortium, Huang, H., Fang, M., Jostins, L., Umićević Mirkov, M., Boucher, G., Anderson, C. A., Andersen, V., Cleynen, I., Cortes, A., et al. (2017) · Nature · doi:10.1038/nature22969 · Cited by 611
Gilhar, A., Etzioni, A., & Paus, R. (2012) · New England Journal of Medicine · doi:10.1056/nejmra1103442 · Cited by 609
Baxi, S., Yang, A., Gennarelli, R. L., Khan, N., Wang, Z., Boyce, L., & Korenstein, D. (2018) · BMJ · doi:10.1136/bmj.k793 · Cited by 578
Neurological adverse events associated with immune checkpoint inhibitors: Review of the literature
Cuzzubbo, S., Javeri, F., Tissier, M., Roumi, A., Barlog, C., Doridam, J., Lebbe, C., Belin, C., Ursu, R., & Carpentier, A. F. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2016.12.001 · Cited by 571
Weber, J., Thompson, J. A., Hamid, O., Minor, D., Amin, A., Ron, I., Ridolfi, R., Assi, H., Maraveyas, A., Berman, D., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1024 · Cited by 568
Plenge, R. M., Padyukov, L., Remmers, E. F., Purcell, S., Lee, A. T., Karlson, E. W., Wolfe, F., Kastner, D. L., Alfredsson, L., Altshuler, D., et al. (2005) · The American Journal of Human Genetics · doi:10.1086/498651 · Cited by 564
Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy
Zimmer, L., Goldinger, S. M., Hofmann, L., Loquai, C., Ugurel, S., Thomas, I., Schmidgen, M. I., Gutzmer, R., Utikal, J. S., Göppner, D., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.02.024 · Cited by 562
Rozeman, E. A., Menzies, A. M., van Akkooi, A. C. J., Adhikari, C., Bierman, C., van de Wiel, B. A., Scolyer, R. A., Krijgsman, O., Sikorska, K., Eriksson, H., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30151-2 · Cited by 537
Self-citationMeta-analysis of genome-wide association study data identifies additional type 1 diabetes risk loci
Cooper, J. D., Smyth, D. J., Smiles, A. M., Plagnol, V., Walker, N. M., Allen, J. E., Downes, K., Barrett, J. C., Healy, B. C., Mychaleckyj, J. C., et al. (2008) · Nature Genetics · doi:10.1038/ng.249 · Cited by 531
Sarcoidosis is associated with a truncating splice site mutation in BTNL2
Valentonyte, R., Hampe, J., Huse, K., Rosenstiel, P., Albrecht, M., Stenzel, A., Nagy, M., Gaede, K. I., Franke, A., Haesler, R., et al. (2005) · Nature Genetics · doi:10.1038/ng1519 · Cited by 491
De Velasco, G., Je, Y., Bossé, D., Awad, M. M., Ott, P. A., Moreira, R. B., Schutz, F., Bellmunt, J., Sonpavde, G. P., Hodi, F. S., et al. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0237 · Cited by 486
Locharernkul, C., Loplumlert, J., Limotai, C., Korkij, W., Desudchit, T., Tongkobpetch, S., Kangwanshiratada, O., Hirankarn, N., Suphapeetiporn, K., & Shotelersuk, V. (2008) · Epilepsia · doi:10.1111/j.1528-1167.2008.01719.x · Cited by 482
Voskens, C. J., Goldinger, S. M., Loquai, C., Robert, C., Kaehler, K. C., Berking, C., Bergmann, T., Bockmeyer, C. L., Eigentler, T., Fluck, M., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0053745 · Cited by 468
Velaga, M. R., Wilson, V., Jennings, C. E., Owen, C. J., Herington, S., Donaldson, P. T., Ball, S. G., James, R. A., Quinton, R., Perros, P., et al. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1108 · Cited by 467
A common sex-dependent mutation in a RET enhancer underlies Hirschsprung disease risk
Emison, E. S., McCallion, A. S., Kashuk, C. S., Bush, R. T., Grice, E., Lin, S., Portnoy, M. E., Cutler, D. J., Green, E. D., & Chakravarti, A. (2005) · Nature · doi:10.1038/nature03467 · Cited by 462
Abdel-Wahab, N., Shah, M., & Suarez-Almazor, M. E. (2016) · PLOS ONE · doi:10.1371/journal.pone.0160221 · Cited by 444
The melanoma revolution: From UV carcinogenesis to a new era in therapeutics
Lo, J. A., & Fisher, D. E. (2014) · Science · doi:10.1126/science.1253735 · Cited by 427
Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer
Drake, C. G., Lipson, E. J., & Brahmer, J. R. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.208 · Cited by 422
Variant of TYR and Autoimmunity Susceptibility Loci in Generalized Vitiligo
Jin, Y., Birlea, S. A., Fain, P. R., Gowan, K., Riccardi, S. L., Holland, P. J., Mailloux, C. M., Sufit, A. J. D., Hutton, S. M., Amadi-Myers, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0908547 · Cited by 415
Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients
Delaunay, M., Cadranel, J., Lusque, A., Meyer, N., Gounant, V., Moro-Sibilot, D., Michot, J.-M., Raimbourg, J., Girard, N., Guisier, F., et al. (2017) · European Respiratory Journal · doi:10.1183/13993003.00050-2017 · Cited by 412
Villadolid, J. J., & Amin, A. (2015) · PubMed · doi:10.3978/j.issn.2218-6751.2015.06.06 · Cited by 409
Cappelli, L. C., Gutierrez, A. K., Bingham, C. O., & Shah, A. A. (2017) · Arthritis Care & Research · doi:10.1002/acr.23177 · Cited by 403
Anti–PD-1–Related Pneumonitis during Cancer Immunotherapy
Nishino, M., Sholl, L. M., Hatabu, H., Ramaiya, N. H., & Hodi, F. S. (2015) · New England Journal of Medicine · doi:10.1056/nejmc1505197 · Cited by 373
Genome-wide association analyses identify 13 new susceptibility loci for generalized vitiligo
Jin, Y., Birlea, S. A., Fain, P. R., Ferrara, T. M., Ben, S., Riccardi, S. L., Cole, J. B., Gowan, K., Holland, P. J., Bennett, D. C., et al. (2012) · Nature Genetics · doi:10.1038/ng.2272 · Cited by 353
The etiology of autoimmune thyroid disease: A story of genes and environment
Tomer, Y., & Huber, A. (2009) · Journal of Autoimmunity · doi:10.1016/j.jaut.2009.02.007 · Cited by 351
Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancer
Touat, M., Maisonobe, T., Knauss, S., Ben Hadj Salem, O., Hervier, B., Auré, K., Szwebel, T.-A., Kramkimel, N., Lethrosne, C., Bruch, J.-F., et al. (2018) · Neurology · doi:10.1212/wnl.0000000000006124 · Cited by 342
Leonardi, G. C., Gainor, J. F., Altan, M., Kravets, S., Dahlberg, S. E., Gedmintas, L., Azimi, R., Rizvi, H., Riess, J. W., Hellmann, M. D., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.77.0305 · Cited by 341
Cancer Immunotherapy with Anti-CTLA-4 Monoclonal Antibodies Induces an Inflammatory Bowel Disease
Marthey, L., Mateus, C., Mussini, C., Nachury, M., Nancey, S., Grange, F., Zallot, C., Peyrin-Biroulet, L., Rahier, J. F., Bourdier de Beauregard, M., et al. (2016) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjv227 · Cited by 340
Läubli, H., Balmelli, C., Bossard, M., Pfister, O., Glatz, K., & Zippelius, A. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-015-0057-1 · Cited by 319
Genome-Wide Association Study Identifies Variants Associated With Autoimmune Hepatitis Type 1
de Boer, Y. S., van Gerven, N. M. F., Zwiers, A., Verwer, B. J., van Hoek, B., van Erpecum, K. J., Beuers, U., van Buuren, H. R., Drenth, J. P. H., den Ouden, J. W., et al. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.04.022 · Cited by 304
Anti-CTLA4 Antibody–Induced Lupus Nephritis
Fadel, F., Karoui, K. E., & Knebelmann, B. (2009) · New England Journal of Medicine · doi:10.1056/nejmc0904283 · Cited by 300
Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma
Liao, B., Shroff, S., Kamiya-Matsuoka, C., & Tummala, S. (2014) · Neuro-Oncology · doi:10.1093/neuonc/nou001 · Cited by 288
Sznol, M., Ferrucci, P. F., Hogg, D., Atkins, M. B., Wolter, P., Guidoboni, M., Lebbé, C., Kirkwood, J. M., Schachter, J., Daniels, G. A., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.72.1167 · Cited by 286
Allelic basis for HLA-encoded susceptibility to type 1 autoimmune hepatitis
Strettell, M., Donaldson, P., Thomson, L., Santrach, P., Moore, S., Czaja, A., & Williams, R. (1997) · Gastroenterology · doi:10.1053/gast.1997.v112.pm9178696 · Cited by 277
Hu, X., Deutsch, A. J., Lenz, T. L., Onengut-Gumuscu, S., Han, B., Chen, W.-M., Howson, J. M. M., Todd, J. A., de Bakker, P. I. W., Rich, S. S., et al. (2015) · Nature Genetics · doi:10.1038/ng.3353 · Cited by 271
Genome-wide association study identifies ANXA11 as a new susceptibility locus for sarcoidosis
Hofmann, S., Franke, A., Fischer, A., Jacobs, G., Nothnagel, M., Gaede, K. I., Schürmann, M., Müller-Quernheim, J., Krawczak, M., Rosenstiel, P., et al. (2008) · Nature Genetics · doi:10.1038/ng.198 · Cited by 269
Larkin, J., Chmielowski, B., Lao, C. D., Hodi, F. S., Sharfman, W., Weber, J., Suijkerbuijk, K. P. M., Azevedo, S., Li, H., Reshef, D., et al. (2017) · The Oncologist · doi:10.1634/theoncologist.2016-0487 · Cited by 267
Myasthenia gravis: An emerging toxicity of immune checkpoint inhibitors
Makarious, D., Horwood, K., & Coward, J. I. G. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.05.041 · Cited by 262
Spain, L., Walls, G., Julve, M., O’Meara, K., Schmid, T., Kalaitzaki, E., Turajlic, S., Gore, M., Rees, J., & Larkin, J. (2017) · Annals of Oncology · doi:10.1093/annonc/mdw558 · Cited by 260
Autoimmune diseases — connecting risk alleles with molecular traits of the immune system
Gutierrez-Arcelus, M., Rich, S. S., & Raychaudhuri, S. (2016) · Nature Reviews Genetics · doi:10.1038/nrg.2015.33 · Cited by 256 · cited 1×
“Genome-wide association studies (GWAS) have uncovered hundreds of risk loci for AID, although it remains to be elucidated how risk variants affect gene regulation and immune function.(23) Treatment with immune CPI antibodies in patients with pre-existing risk loci for AID could trigger an erroneous immune response tha…”
BackgroundCardiotoxicity of immune checkpoint inhibitors
Varricchi, G., Galdiero, M. R., Marone, G., Criscuolo, G., Triassi, M., Bonaduce, D., Marone, G., & Tocchetti, C. G. (2017) · ESMO Open · doi:10.1136/esmoopen-2017-000247 · Cited by 246
Zhou, W., Otto, E. A., Cluckey, A., Airik, R., Hurd, T. W., Chaki, M., Diaz, K., Lach, F. P., Bennett, G. R., Gee, H. Y., et al. (2012) · Nature Genetics · doi:10.1038/ng.2347 · Cited by 243
Tackenberg, B., Jelčić, I., Baerenwaldt, A., Oertel, W. H., Sommer, N., Nimmerjahn, F., & Lünemann, J. D. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0807319106 · Cited by 242
Ascierto, P. A., Melero, I., Bhatia, S., Bono, P., Sanborn, R. E., Lipson, E. J., Callahan, M. K., Gajewski, T., Gomez-Roca, C. A., Hodi, F. S., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.9520 · Cited by 238 · cited 1×
“relatlimab (anti-lymphocyte activation gene 3 (LAG-3)), can overcome resistance to antiPD-1 monotherapy.(6) Moving combination immunotherapy to earlier stages of disease seems to increase the response rate further, but at cost of higher incidence of severe toxicities.”
BackgroundVedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis
Bergqvist, V., Hertervig, E., Gedeon, P., Kopljar, M., Griph, H., Kinhult, S., Carneiro, A., & Marsal, J. (2017) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-017-1962-6 · Cited by 234
Diverse types of dermatologic toxicities from immune checkpoint blockade therapy
Curry, J. L., Tetzlaff, M. T., Nagarajan, P., Drucker, C., Diab, A., Hymes, S. R., Duvic, M., Hwu, W., Wargo, J. A., Torres‐Cabala, C. A., et al. (2017) · Journal of Cutaneous Pathology · doi:10.1111/cup.12858 · Cited by 232
Gonzalez, R. S., Salaria, S. N., Bohannon, C. D., Huber, A. R., Feely, M. M., & Shi, C. (2017) · Histopathology · doi:10.1111/his.13118 · Cited by 228
Cutaneous adverse effects of the immune checkpoint inhibitors
Collins, L. K., Chapman, M. S., Carter, J. B., & Samie, F. H. (2017) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2016.12.001 · Cited by 219
Immune Checkpoint Inhibitors: New Insights and Current Place in Cancer Therapy
La‐Beck, N. M., Jean, G. W., Huynh, C., Alzghari, S. K., & Lowe, D. B. (2015) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1643 · Cited by 216
Neurologic complications of immune checkpoint inhibitors
Hottinger, A. F. (2016) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000391 · Cited by 207
A Genome-Wide Association Study of Myasthenia Gravis
Renton, A. E., Pliner, H. A., Provenzano, C., Evoli, A., Ricciardi, R., Nalls, M. A., Marangi, G., Abramzon, Y., Arepalli, S., Chong, S., et al. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2014.4103 · Cited by 206
Immunoregulatory functions of VISTA
Nowak, E. C., Lines, J. L., Varn, F. S., Deng, J., Sarde, A., Mabaera, R., Kuta, A., Le Mercier, I., Cheng, C., & Noelle, R. J. (2017) · Immunological Reviews · doi:10.1111/imr.12525 · Cited by 197
A common mutation in the surfactant protein C gene associated with lung disease
Cameron, H. S., Somaschini, M., Carrera, P., Hamvas, A., Whitsett, J. A., Wert, S. E., Deutsch, G., & Nogee, L. M. (2005) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2004.10.028 · Cited by 188
Pulmonary Sarcoid-Like Granulomatosis Induced by Ipilimumab
Berthod, G., Lazor, R., Letovanec, I., Romano, E., Noirez, L., Mazza Stalder, J., Speiser, D. E., Peters, S., & Michielin, O. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.3298 · Cited by 182
Tohkin, M., Kaniwa, N., Saito, Y., Sugiyama, E., Kurose, K., Nishikawa, J., Hasegawa, R., Aihara, M., Matsunaga, K., Abe, M., et al. (2013) · The Pharmacogenomics Journal · doi:10.1038/tpj.2011.41 · Cited by 181
Frequent loss of HLA alleles associated with copy number-neutral 6pLOH in acquired aplastic anemia
Katagiri, T., Sato-Otsubo, A., Kashiwase, K., Morishima, S., Sato, Y., Mori, Y., Kato, M., Sanada, M., Morishima, Y., Hosokawa, K., et al. (2011) · Blood · doi:10.1182/blood-2011-07-365189 · Cited by 181
Genetic heterogeneity in susceptibility to autoimmune hepatitis types 1 and 2
Bittencourt, P. (1999) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(99)00285-3 · Cited by 176
Anti-CTLA-4 antibody-induced Guillain–Barré syndrome in a melanoma patient
Wilgenhof, S., & Neyns, B. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr028 · Cited by 175
Carrozzo, M., Uboldi de capei, M., Dametto, E., Fasano, M. E., Arduino, P., Broccoletti, R., Vezza, D., Rendine, S., Curtoni, E. S., & Gandolfo, S. (2004) · Journal of Investigative Dermatology · doi:10.1046/j.0022-202x.2003.22108.x · Cited by 173
Inflammatory CNS disease caused by immune checkpoint inhibitors: status and perspectives
Yshii, L. M., Hohlfeld, R., & Liblau, R. S. (2017) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.144 · Cited by 173
A review of bullous pemphigoid associated with PD‐1 and PD‐L1 inhibitors
Lopez, A. T., Khanna, T., Antonov, N., Audrey‐Bayan, C., & Geskin, L. (2018) · International Journal of Dermatology · doi:10.1111/ijd.13984 · Cited by 171
Association of ABCB1 genotypes with paclitaxel-mediated peripheral neuropathy and neutropenia
Sissung, T. M., Mross, K., Steinberg, S. M., Behringer, D., Figg, W. D., Sparreboom, A., & Mielke, S. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2006.06.017 · Cited by 170
Robinson, M. R., Chan, C.-C., Yang, J. C., Rubin, B. I., Gracia, G. J., Sen, H. N., Csaky, K. G., & Rosenberg, S. A. (2004) · Journal of Immunotherapy · doi:10.1097/00002371-200411000-00008 · Cited by 159
GWAS identifies novel SLE susceptibility genes and explains the association of the HLA region
Armstrong, D. L., Zidovetzki, R., Alarcón-Riquelme, M. E., Tsao, B. P., Criswell, L. A., Kimberly, R. P., Harley, J. B., Sivils, K. L. M., Vyse, T. J., Gaffney, P. M., et al. (2014) · Genes and Immunity · doi:10.1038/gene.2014.23 · Cited by 157
Mutations in SGOL1 cause a novel cohesinopathy affecting heart and gut rhythm
Chétaille, P., Preuß, C., Burkhard, S. B., Côté, J.-M., Houde, C., Castilloux, J., Piché, J., Gosset, N., Leclerc, S., Wünnemann, F., et al. (2014) · Nature Genetics · doi:10.1038/ng.3113 · Cited by 154
Geisler, B. P., Raad, R. A., Esaian, D., Sharon, E., & Schwartz, D. R. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-015-0048-2 · Cited by 144
SLCO1B1 Variants and Statin-Induced Myopathy — A Genomewide Study
Act, A. (2008) · Cited by 142
Anti-CTLA4 Monoclonal Antibody Induced Sarcoidosis in a Metastatic Melanoma Patient
Eckert, A., Schoeffler, A., Dalle, S., Phan, A., Kiakouama, L., & Thomas, L. (2008) · Dermatology · doi:10.1159/000161122 · Cited by 138
Contribution of rare and common variants determine complex diseases—Hirschsprung disease as a model
Alves, M. M., Sribudiani, Y., Brouwer, R. W. W., Amiel, J., Antiñolo, G., Borrego, S., Ceccherini, I., Chakravarti, A., Fernández, R. M., García-Barceló, M.-M., et al. (2013) · Developmental Biology · doi:10.1016/j.ydbio.2013.05.019 · Cited by 136
GWAS in autoimmune thyroid disease: redefining our understanding of pathogenesis
Simmonds, M. J. (2013) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2013.56 · Cited by 131
Robert, C., & Ghiringhelli, F. (2009) · The Oncologist · doi:10.1634/theoncologist.2009-0028 · Cited by 129
Ipilimumab-induced Ocular and Orbital Inflammation—A Case Series and Review of the Literature
Papavasileiou, E., Prasad, S., Freitag, S. K., Sobrin, L., & Lobo, A.-M. (2015) · Ocular Immunology and Inflammation · doi:10.3109/09273948.2014.1001858 · Cited by 127
Ipilimumab-Induced Sarcoidosis in a Patient With Metastatic Melanoma Undergoing Complete Remission
Vogel, W. V., Guislain, A., Kvistborg, P., Schumacher, T. N., Haanen, J. B. A. G., & Blank, C. U. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.9693 · Cited by 127
Descamps, V., & Ranger‐Rogez, S. (2013) · Joint Bone Spine · doi:10.1016/j.jbspin.2013.05.002 · Cited by 125
Common variants in the HLA-DQ region confer susceptibility to idiopathic achalasia
Gockel, I., Becker, J., Wouters, M. M., Niebisch, S., Gockel, H. R., Hess, T., Ramonet, D., Zimmermann, J., Vigo, A., Trynka, G., et al. (2014) · Nature Genetics · doi:10.1038/ng.3029 · Cited by 123
Chae, Y. K., Chiec, L., Mohindra, N., Gentzler, R., Patel, J., & Giles, F. (2017) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-016-1913-7 · Cited by 121
Drug-Induced Graves Disease From CTLA-4 Receptor Suppression
Borodic, G., Hinkle, D. M., & Cia, Y. (2011) · Ophthalmic Plastic & Reconstructive Surgery · doi:10.1097/iop.0b013e3181ef72a1 · Cited by 120
Chan, M. M. K., Kefford, R. F., Carlino, M., Clements, A., & Manolios, N. (2015) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000060 · Cited by 119
Tetzlaff, M. T., Nagarajan, P., Chon, S., Huen, A., Diab, A., Omar, P., Aung, P. P., Torres-Cabala, C. A., Mays, S. R., Prieto, V. G., et al. (2017) · The American Journal of Dermatopathology · doi:10.1097/dad.0000000000000688 · Cited by 114
Zarbo, A., Belum, V. R., Sibaud, V., Oudard, S., Postow, M. A., Hsieh, J. J., Motzer, R. J., Busam, K. J., & Lacouture, M. E. (2017) · British Journal of Dermatology · doi:10.1111/bjd.15237 · Cited by 113
Genetic analysis of the HLA region of Japanese patients with type 1 autoimmune hepatitis
Yoshizawa, K., Ôta, M., Katsuyama, Y., Ichijo, T., Matsumoto, A., Tanaka, E., & Kiyosawa, K. (2005) · Journal of Hepatology · doi:10.1016/j.jhep.2004.12.019 · Cited by 110
Hou, S., Du, L., Lei, B., Pang, C. P., Zhang, M., Zhuang, W., Zhang, M., Huang, L., Gong, B., Wang, M., et al. (2014) · Nature Genetics · doi:10.1038/ng.3061 · Cited by 106
Autoimmune Inflammatory Myopathy after Treatment with Ipilimumab
Hunter, G. R. W., Voll, C., & Robinson, C. A. (2009) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100007939 · Cited by 105
Loochtan, A. I., Nickolich, M. S., & Hobson‐Webb, L. D. (2015) · Muscle & Nerve · doi:10.1002/mus.24648 · Cited by 101
Klein, O., Ebert, L. M., Nicholaou, T., Browning, J., Russell, S. E., Zuber, M., Jackson, H. M., Dimopoulos, N., Tan, B. S., Hoos, A., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2424 · Cited by 101
Exacerbation of Psoriasis During Nivolumab Therapy for Metastatic Melanoma
Matsumura, N., Ohtsuka, M., Kikuchi, N., & Yamamoto, T. (2016) · Acta Dermato Venereologica · doi:10.2340/00015555-2212 · Cited by 99
Hemophilia A Induced by Ipilimumab
Delyon, J., Mateus, C., & Lambert, T. (2011) · New England Journal of Medicine · doi:10.1056/nejmc1110923 · Cited by 98
Severe relapse in a multiple sclerosis patient associated with ipilimumab treatment of melanoma
Gettings, E. J., Hackett, C., & Scott, T. F. M. (2014) · Multiple Sclerosis Journal · doi:10.1177/1352458514549403 · Cited by 98
Gaudy-Marqueste, C., Monestier, S., Franques, J., Cantais, E., Richard, M.-A., & Grob, J.-J. (2013) · Journal of Immunotherapy · doi:10.1097/cji.0b013e31827807dd · Cited by 94
Vogt-Koyanagi-Harada-like Syndrome After CTLA-4 Inhibition With Ipilimumab for Metastatic Melanoma
Crosson, J. N., Laird, P. W., Debiec, M., Bergstrom, C. S., Lawson, D. H., & Yeh, S. (2015) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000066 · Cited by 91
Neutropenia in a Patient Treated With Ipilimumab (anti–CTLA-4 Antibody)
Akhtari, M., Waller, E. K., Jaye, D. L., Lawson, D. H., Ibrahim, R., Papadopoulos, N. E., & Arellano, M. L. (2009) · Journal of Immunotherapy · doi:10.1097/cji.0b013e31819aa40b · Cited by 89
Murphy, K. P., Kennedy, M. P., Barry, J. E., O'Regan, K. N., & Power, D. G. (2014) · Oncology Research and Treatment · doi:10.1159/000362614 · Cited by 88
Achyut, B. R., Ghoshal, U. C., Moorchung, N., & Mittal, B. (2007) · Human Immunology · doi:10.1016/j.humimm.2007.10.006 · Cited by 88
Bhatia, S., Huber, B. R., Upton, M. P., & Thompson, J. A. (2009) · Journal of Immunotherapy · doi:10.1097/cji.0b013e318193a206 · Cited by 88
Mutations in RAD21 Disrupt Regulation of APOB in Patients With Chronic Intestinal Pseudo-Obstruction
Bonora, E., Bianco, F., Cordeddu, L., Bamshad, M. J., Francescatto, L., Dowless, D., Stanghellini, V., Cogliandro, R. F., Lindberg, G., Mungan, Z. A., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2014.12.034 · Cited by 87
HLA antigens in the Landry‐Guillain‐Barré syndrome and chronic relapsing polyneuritis
Stewart, G. J., Pollard, J. D., McLeod, J. G., & Wolnizer, C. M. (1978) · Annals of Neurology · doi:10.1002/ana.410040317 · Cited by 85
Tanaka, R., Maruyama, H., Tomidokoro, Y., Yanagiha, K., Hirabayashi, T., Ishii, A., Okune, M., Inoue, S., Sekine, I., Tamaoka, A., et al. (2016) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyw090 · Cited by 84
Immune-mediated red cell aplasia after anti-CTLA-4 immunotherapy for metastatic melanoma
Gordon, I. O., Wade, T., Chin, K. M., Dickstein, J. I., & Gajewski, T. F. (2008) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-008-0627-x · Cited by 81
NOD2 (CARD15) , the first susceptibility gene for Crohn's disease
McGovern, D. P. B., van Heel, D. A., AHMAD, T., & Jewell, D. P. (2001) · Gut · doi:10.1136/gut.49.6.752 · Cited by 81
Cutaneous and pulmonary sarcoidosis-like reaction associated with ipilimumab
Reule, R. B., & North, J. P. (2013) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2013.07.028 · Cited by 80
Association between MUC5B and TERT polymorphisms and different interstitial lung disease phenotypes
Wei, R., Li, C., Zhang, M., Jones-Hall, Y. L., Myers, J. L., Noth, I., & Liu, W. (2014) · Translational Research · doi:10.1016/j.trsl.2013.12.006 · Cited by 80
Wong, R. K., Lee, J. K., & Huang, J. J. (2012) · RETINAL Cases & Brief Reports · doi:10.1097/icb.0b013e31824f7130 · Cited by 80
FOXP3: Genetic and epigenetic implications for autoimmunity
Katoh, H., Zheng, P., & Liu, Y. (2013) · Journal of Autoimmunity · doi:10.1016/j.jaut.2012.12.004 · Cited by 73
Hofner, P., Gyulai, Z., Kiss, Z. F., Tiszai, A., Tiszlavicz, L., Tóth, G., Szőke, D., Molnar, B. A., Lonovics, J., Tulassay, Z., et al. (2007) · Helicobacter · doi:10.1111/j.1523-5378.2007.00481.x · Cited by 73
Ipilimumab-Associated Bilateral Optic Neuropathy
Yeh, O. L., & Francis, C. E. (2015) · Journal of Neuro-Ophthalmology · doi:10.1097/wno.0000000000000217 · Cited by 73
Severity of Guillain–Barré syndrome is associated with Fcγ Receptor III polymorphisms
van Sorge, N. M., van der Pol, W. L., Jansen, M., Geleijns, K. P. W., Kalmijn, S., Hughes, R. A., Rees, J. H., Pritchard, J., Vedeler, C. A., Myhr, K., et al. (2005) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2005.01.016 · Cited by 71
Shum, A., DeVoss, J., Tan, C. L., Hou, Y.-F., Johannes, K. P. A., O'Gorman, C., Jones, K., Sochett, E., Fong, L., & Anderson, M. S. (2009) · Science Translational Medicine · doi:10.1126/scitranslmed.3000284 · Cited by 71
Chronic inflammatory demyelinating polyneuropathy associated with carcinoma.
Antoine, J.-C. G., Mosnier, J., Lapras, J., Convers, P., Absi, L., Laurent, B., & Michel, D. (1996) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.60.2.188 · Cited by 68 · cited 1×
“It is most likely also CPI induced and less likely part of a paraneoplastic syndrome, since CIDP and malignant disease are only rarely seen concurrently.(32) CIDP”
BackgroundMolecular Genetic of Atopic Dermatitis : An Update
Al‐Shobaili, H. A., Ahmed, A. A., AlNomair, N., Alobead, Z. A., & Rasheed, Z. (2016) · International Journal of Health Sciences · doi:10.12816/0031218 · Cited by 68
Association Between Ipilimumab and Celiac Disease
Gentile, N. M., D’Souza, A., Fujii, L. L., Wu, T., & Murray, J. A. (2013) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2013.01.015 · Cited by 65
Andersen, R., Nørgaard, P., Al-Jailawi, M. K. M., & Svane, I. M. (2014) · OncoImmunology · doi:10.4161/21624011.2014.954506 · Cited by 63
Inverse Psoriasiform Eruption During Pembrolizumab Therapy for Metastatic Melanoma
Totonchy, M. B., Ezaldein, H. H., Ko, C. J., & Choi, J. N. (2015) · JAMA Dermatology · doi:10.1001/jamadermatol.2015.5210 · Cited by 63
Martínez-Carrillo, D. N., Garza‐González, E., Betancourt-Linares, R., Mónico-Manzano, T., Antúnez-Rivera, C., Román-Román, A., Flores‐Alfaro, E., Illades‐Aguiar, B., & Fernández‐Tilapa, G. (2010) · BMC Gastroenterology · doi:10.1186/1471-230x-10-126 · Cited by 61
Tissot, C., Carsin, A., Freymond, N., Pacheco, Y., & Devouassoux, G. (2013) · European Respiratory Journal · doi:10.1183/09031936.00107912 · Cited by 60
An Association Between RRM1 Haplotype and Gemcitabine-Induced Neutropenia in Breast Cancer Patients
Rha, S. Y., Jeung, H., Choi, Y. H., Yang, W. I., Yoo, J. H., Kim, B., Roh, J. K., & Chung, H. C. (2007) · The Oncologist · doi:10.1634/theoncologist.12-6-622 · Cited by 60
Eggermont, A. M. M., & Dummer, R. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.09.014 · Cited by 59
Lethal aplastic anemia caused by dual immune checkpoint blockade in metastatic melanoma
Helgadóttir, H., Kis, L. L., Ljungman, P. T., Larkin, J., Kefford, R. F., Ascierto, P. A., Hansson, J., & Masucci, G. V. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx177 · Cited by 57
Genetic markers in acquired haemophilia
Oldenburg, J., Zeitler, H.-J., & Pavlova, A. (2010) · Haemophilia · doi:10.1111/j.1365-2516.2010.02259.x · Cited by 56
Identifying Candidate Hirschsprung Disease–Associated RET Variants
Burzynski, G. M., Nolte, I. M., Bronda, A., Bos, K. K., Osinga, J., Plaza-Menacho, I., Twigt, B. A., Maas, S. M., Brooks, A. S., Verheij, B. G. M. J., et al. (2005) · The American Journal of Human Genetics · doi:10.1086/429589 · Cited by 55
Peripheral Neuropathy Associated With Ipilimumab: A Report of 2 Cases
Thaipisuttikul, I., Chapman, P., & Avila, E. K. (2015) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000070 · Cited by 54
Genetic polymorphisms of macrophage-mediators in Guillain–Barré syndrome
Geleijns, K. P. W., Emonts, M., Laman, J. D., van Rijs, W., van Doorn, P. A., Hermans, P. W. M., & Jacobs, B. C. (2007) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2007.07.008 · Cited by 50
Age‐dependent association of idiopathic achalasia with vasoactive intestinal peptide receptor 1 gene
Paladini, F., Cocco, E. E., Cascino, I., Belfiore, F., Badiali, D., Piretta, L., Alghisi, F., Anzini, F., Fiorillo, M. T., Corazziari, E. S., et al. (2009) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2009.01284.x · Cited by 50
Genetic variation in telomeric repeat binding factors 1 and 2 in aplastic anemia
Savage, S. A., Calado, R. T., Xin, Z.-T., Ly, H., Young, N. S., & Chanock, S. J. (2006) · Experimental Hematology · doi:10.1016/j.exphem.2006.02.008 · Cited by 47
McCombe, P., Csurhes, P. A., & Greer, J. M. (2006) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2006.07.017 · Cited by 47
Genetics of enteric neuropathies
Brosens, E., Burns, A. J., Brooks, A. S., Matera, I., Borrego, S., Ceccherini, I., Tam, P. K. H., García-Barceló, M.-M., Thapar, N., Benninga, M. A., et al. (2016) · Developmental Biology · doi:10.1016/j.ydbio.2016.07.008 · Cited by 47
Abdel-Rahman, O., & Fouad, M. (2016) · Immunotherapy · doi:10.2217/imt-2015-0020 · Cited by 46
Multifocal bilateral choroidal neovascularization in a patient on ipilimumab for metastatic melanoma
Modjtahedi, B. S., Maïbach, H. I., & Park, S. (2013) · Cutaneous and Ocular Toxicology · doi:10.3109/15569527.2013.781618 · Cited by 45
Rich, S. S., WEITKAMP, L. R., & Barbosa, J. (1984) · PubMed · Cited by 44
Genetics of human enteric neuropathies
Panza, E., Knowles, C. H., Graziano, C., Thapar, N., Burns, A. J., Seri, M., Stanghellini, V., & GIORGIO, R. D. (2012) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2012.01.001 · Cited by 44
Association between idiopathic achalasia and IL23R gene
de León, A. R., Serna, J. P. D. L., Santiago, J. L., Mantilla, C. S., Fernández‐Arquero, M., de la Concha, E. G., Nuñez, C., Urcelay, E., & Vigo, A. (2010) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2010.01497.x · Cited by 40
Kano, Y., Hirahara, K., Asano, Y., & Shiohara, T. (2008) · Acta Dermato Venereologica · doi:10.2340/00015555-0528 · Cited by 39
Lymphocytic Vasculitis of the Uterus in a Patient With Melanoma Receiving Ipilimumab
Minor, D. R., Bunker, S. R., & Doyle, J. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.5095 · Cited by 37
Human leukocyte antigen class ii associations in patients with idiopathic dilated cardiomyopathy1
Lozano, M. C. G., Rubocki, R. J., WILSON, J., McManus, B. M., Wisecarver, J. L., & MYOCARDITISTREATMENTTRIALINVEST (1997) · Journal of Cardiac Failure · doi:10.1016/s1071-9164(97)90041-5 · Cited by 34
Association of IL10 promoter polymorphisms with idiopathic achalasia
Nuñez, C., García-González, M. A., Santiago, J. L., Benito‐Martín, M. S., Mearin, F., de la Concha, E. G., de la Serna, J. P., de León, A. R., Urcelay, E., & Vigo, A. (2011) · Human Immunology · doi:10.1016/j.humimm.2011.05.017 · Cited by 34
HLA ANTIGENS IN GUILLAIN-BARRÉSYNDROME
Adams, D., Gibson, J., Thomas, P. K., Batchelor, J. R., Hughes, R. A., Kennedy, L. J., Festenstein, H., & Sachs, J. A. (1977) · The Lancet · doi:10.1016/s0140-6736(77)91626-9 · Cited by 33
Notturno, F., Pace, M., Angelis, M. V. D., Caporale, C. M., Giovannini, A., & Uncini, A. (2008) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2008.04.003 · Cited by 33
Cytotoxic T-Lymphocyte Antigen-4 Blockade in Melanoma
Buchbinder, E. I., & McDermott, D. F. (2015) · Clinical Therapeutics · doi:10.1016/j.clinthera.2015.02.003 · Cited by 33
Verny, C., Amati‐Bonneau, P., Letournel, F., Person, B., Dib, N., Malinge, M., Slama, A., Maréchal, C. L., Férec, C., Procaccio, V., et al. (2008) · Diabetes & Metabolism · doi:10.1016/j.diabet.2008.06.001 · Cited by 32
Wong, K. H., Rong, S. S., Chong, K. K. L., Young, A. L., Pang, C. P., & Chen, L. J. (2015) · Scientific Reports · doi:10.1038/srep16672 · Cited by 31
An SNP in CYP39A1 is associated with severe neutropenia induced by docetaxel
Uchiyama, T., Kanno, H., Ishitani, K., Fujii, H., Ohta, H., Matsui, H., Kamatani, N., & Saito, K. (2012) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-012-1872-4 · Cited by 30
Vaughan, R. W., Adam, A.-M., Gray, I. A., Hughes, R. A., Sanders, E. A. C. M., Dam, M., & Welsh, K. I. (1990) · Journal of Neuroimmunology · doi:10.1016/0165-5728(90)90064-t · Cited by 27
Research works printed but not linked: 1
- Petukhova, 2010, Genome-wide association study in alopecia areata implicates both innate and adaptive immunity, Nature, 466, 113, 10.1038/nature09114 · DOI · Paper page
Cited by
Hallmarks of response, resistance, and toxicity to immune checkpoint blockade
Morad, G., Helmink, B. A., Sharma, P., & Wargo, J. A. (2021) · Cell · doi:10.1016/j.cell.2021.09.020 · Cited by 1,648
Moving towards personalized treatments of immune-related adverse events
Esfahani, K., Elkrief, A., Calabrese, C., Lapointe, R., Hudson, M., Routy, B., Miller, W. H., & Calabrese, L. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0352-8 · Cited by 351
Classical Examples of the Concept of the ASIA Syndrome
Borba, V. V., Malkova, A. M., Basantsova, N. Y., Halpert, G., Andréoli, L., Tincani, A., Amital, H., & Shoenfeld, Y. (2020) · Biomolecules · doi:10.3390/biom10101436 · Cited by 115
Yin, J., Wu, Y., Yang, X., Gan, L., & Xue, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.830631 · Cited by 120
Casagrande, S., Sopetto, G. B., Bertalot, G., Bortolotti, R., Racanelli, V., Caffo, O., Giometto, B., Berti, A., & Veccia, A. (2024) · Cancers · doi:10.3390/cancers16071440 · Cited by 110
“Additionally, thanks to the “Immunochip project”, relevant loci have been identified in genes involved in the T-cell receptor signaling pathway as susceptibility factors for the development of thyroiditis and endocrinopathies [95].”
Background
Metadata
- Authors
- Hoefsmit, E. P., Rozeman, E. A., Haanen, J. B. A. G., & Blank, C. U.
- Affiliations
- The Netherlands Cancer Institute (NL)
- Corresponding author
- Blank, Christian U.
- Venue
- ESMO Open
- Publisher
- Elsevier BV
- Published
- 2019
- Volume
- 4
- Issue
- 4
- Pages
- e000472
- ISSN
- 2059-7029 (ISSN-L)
- PMC
- PMC6677983
- OpenAlex
- W2962814122
- Cited by
- 29
- References
- 213
- Citations by year
- 2026: 1 · 2024: 4 · 2023: 3 · 2022: 8 · 2021: 3 · 2020: 8 · 2019: 2
- FWCI
- 0.50
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by-nc/4.0/ (vor, 643 d)
- Locations
- ESMO Open (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Leiden Repository (Leiden University) (submittedVersion, cc-by-nc)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Eli Lilly and Company
- Pfizer
- Les Laboratories Pierre Fabre
- Ipsen
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Keywords
- immune-related adverse events, immune checkpoint inhibitors, biomarkers, cancer immunotherapy, CTLA-4, PD-1, genetic susceptibility
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.